These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28633552)

  • 1. Cabozantinib for the treatment of kidney cancer.
    Abdelaziz A; Vaishampayan U
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
    Schmidinger M; Danesi R
    Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
    Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
    Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
    Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
    Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
    Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
    Chen RC; Choueiri TK; Feuilly M; Meng J; Lister J; Marteau F; Falchook AD; Morris MJ; George DJ; Feldman DR
    Cancer; 2020 Dec; 126(24):5311-5318. PubMed ID: 33022096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
    Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
    George DJ; Hessel C; Halabi S; Michaelson MD; Hahn O; Walsh M; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; Morris MJ; Choueiri TK
    Oncologist; 2019 Nov; 24(11):1497-1501. PubMed ID: 31399500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
    Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
    Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
    Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
    BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis.
    Schmidt E; Lister J; Neumann M; Wiecek W; Fu S; Vataire AL; Sostar J; Huang S; Marteau F
    Target Oncol; 2018 Apr; 13(2):205-216. PubMed ID: 29492762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens.
    Tan Z; Völler S; Yin A; Rieborn A; Gelderblom AJ; van der Hulle T; Knibbe CAJ; Moes DJAR
    Clin Pharmacokinet; 2024 Jun; 63(6):857-869. PubMed ID: 38874883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
    Gross-Goupil M; Bodnar L; Campbell MT; Michael A; Venugopal B; Żołnierek J; Dutailly P; Procopio G; Albiges L
    Clin Genitourin Cancer; 2024 Feb; 22(1):84-97. PubMed ID: 38101983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
    Wu Y; Chen S; Yang X; Sato K; Lal P; Wang Y; Shinkle AT; Wendl MC; Primeau TM; Zhao Y; Gould A; Sun H; Mudd JL; Hoog J; Mashl RJ; Wyczalkowski MA; Mo CK; Liu R; Herndon JM; Davies SR; Liu D; Ding X; Evrard YA; Welm BE; Lum D; Koh MY; Welm AL; Chuang JH; Moscow JA; Meric-Bernstam F; Govindan R; Li S; Hsieh J; Fields RC; Lim KH; Ma CX; Zhang H; Ding L; Chen F
    Cancer Res; 2023 Dec; 83(24):4161-4178. PubMed ID: 38098449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.
    Rosellini M; Tassinari E; Marchetti A; Mollica V; Massari F
    Eur Urol; 2024 Jan; 85(1):97-98. PubMed ID: 37777426
    [No Abstract]   [Full Text] [Related]  

  • 16. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.
    Lue HW; Derrick DS; Rao S; Van Gaest A; Cheng L; Podolak J; Lawson S; Xue C; Garg D; White R; Ryan CW; Drake JM; Ritz A; Heiser LM; Thomas GV
    Cell Rep Med; 2021 May; 2(5):100267. PubMed ID: 34095877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis.
    Su J; Ni C; Wu Y; Zhang J; Cai Z; Lu J; Lin S; Wang J
    Expert Rev Anticancer Ther; 2024 May; 24(5):293-302. PubMed ID: 38551185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of c-MET Inhibitors in Cancer.
    Puccini A; Marín-Ramos NI; Bergamo F; Schirripa M; Lonardi S; Lenz HJ; Loupakis F; Battaglin F
    Drug Saf; 2019 Feb; 42(2):211-233. PubMed ID: 30649748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
    Domański P; Piętak M; Staneta S; Fortuniak W; Kruczyk B; Kobiernik A; Bakuła P; Mydlak A; Demkow T; Sikora-Kupis B; Dumnicka P; Kucharz J
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541124
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.
    Gerendash BS; Creel PA
    Onco Targets Ther; 2017; 10():5053-5064. PubMed ID: 29089775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.